Association of systemic corticosteroid use with prognosis of patients with acute exacerbations of chronic obstructive pulmonary disease in the intensive care unit: a propensity score-matched cohort study.

IF 7 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Le Bai, Pengfei Zhu, Tingyu Pan, Yuanjie Liu, Yong Xu, Hailang He, Xianmei Zhou
{"title":"Association of systemic corticosteroid use with prognosis of patients with acute exacerbations of chronic obstructive pulmonary disease in the intensive care unit: a propensity score-matched cohort study.","authors":"Le Bai, Pengfei Zhu, Tingyu Pan, Yuanjie Liu, Yong Xu, Hailang He, Xianmei Zhou","doi":"10.1186/s12916-024-03705-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Systemic corticosteroid has been recommended for the treatment of severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Little is known about the use of systemic corticosteroid in patients admitted to intensive care units (ICU) since most of previous trials excluded these critically ill patients.</p><p><strong>Methods: </strong>We conducted a matched cohort study based on the Medical Information Mart in Intensive Care-IV database. Patients with AECOPD in ICUs were included. Patients in the exposure group should be intravenously administrated with methylprednisolone or treated with oral prednisone within 24 h after ICU admission. The propensity score matching and multivariable analyses were used to adjust for covariates. The primary outcome was 28-day mortality, and secondary outcomes included ICU mortality, in-hospital mortality, the duration of ICU stay, and mechanical ventilation. Subgroup analyses for the primary outcome were performed according to age, sex, type of corticosteroid, type of ICU admission, type of mechanical ventilation, and co-morbidities/complications.</p><p><strong>Results: </strong>The entire cohort and the matched cohort included 763 and 412 patients, respectively. In the matched cohort, the use of systemic corticosteroid had no impact on 28-day mortality (OR: 1.00, 95% CI: 0.61-1.64, P = 1.000). The results kept consistent in all subgroups. Additionally, systemic corticosteroid showed no benefits on ICU mortality, in-hospital mortality, the length of ICU stay, and the duration of mechanical ventilation.</p><p><strong>Conclusions: </strong>The results of this study do not support routine use of systemic corticosteroid in patients with AECOPD admitted to ICUs.</p>","PeriodicalId":9188,"journal":{"name":"BMC Medicine","volume":null,"pages":null},"PeriodicalIF":7.0000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11515503/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12916-024-03705-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Systemic corticosteroid has been recommended for the treatment of severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Little is known about the use of systemic corticosteroid in patients admitted to intensive care units (ICU) since most of previous trials excluded these critically ill patients.

Methods: We conducted a matched cohort study based on the Medical Information Mart in Intensive Care-IV database. Patients with AECOPD in ICUs were included. Patients in the exposure group should be intravenously administrated with methylprednisolone or treated with oral prednisone within 24 h after ICU admission. The propensity score matching and multivariable analyses were used to adjust for covariates. The primary outcome was 28-day mortality, and secondary outcomes included ICU mortality, in-hospital mortality, the duration of ICU stay, and mechanical ventilation. Subgroup analyses for the primary outcome were performed according to age, sex, type of corticosteroid, type of ICU admission, type of mechanical ventilation, and co-morbidities/complications.

Results: The entire cohort and the matched cohort included 763 and 412 patients, respectively. In the matched cohort, the use of systemic corticosteroid had no impact on 28-day mortality (OR: 1.00, 95% CI: 0.61-1.64, P = 1.000). The results kept consistent in all subgroups. Additionally, systemic corticosteroid showed no benefits on ICU mortality, in-hospital mortality, the length of ICU stay, and the duration of mechanical ventilation.

Conclusions: The results of this study do not support routine use of systemic corticosteroid in patients with AECOPD admitted to ICUs.

全身使用皮质类固醇与重症监护病房慢性阻塞性肺病急性加重患者预后的关系:倾向评分匹配队列研究。
背景:系统性皮质类固醇被推荐用于治疗慢性阻塞性肺疾病(AECOPD)的严重急性加重。由于之前的大多数试验都不包括重症监护病房(ICU)的重症患者,因此人们对重症监护病房患者使用全身皮质类固醇的情况知之甚少:我们根据重症监护医学信息市场-IV 数据库进行了一项匹配队列研究。研究纳入了重症监护病房的 AECOPD 患者。暴露组患者应在入住 ICU 后 24 小时内接受甲泼尼龙静脉注射或泼尼松口服治疗。采用倾向评分匹配和多变量分析来调整协变量。主要结果为28天死亡率,次要结果包括ICU死亡率、院内死亡率、ICU住院时间和机械通气。根据年龄、性别、皮质类固醇类型、ICU入院类型、机械通气类型以及合并疾病/并发症对主要结果进行了分组分析:整个队列和匹配队列分别包括 763 名和 412 名患者。在匹配队列中,全身皮质类固醇的使用对 28 天死亡率没有影响(OR:1.00,95% CI:0.61-1.64,P = 1.000)。这一结果在所有亚组中保持一致。此外,全身皮质类固醇对重症监护病房死亡率、院内死亡率、重症监护病房住院时间和机械通气时间均无益处:本研究结果不支持在重症监护室收治的 AECOPD 患者中常规使用全身皮质类固醇。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Medicine
BMC Medicine 医学-医学:内科
CiteScore
13.10
自引率
1.10%
发文量
435
审稿时长
4-8 weeks
期刊介绍: BMC Medicine is an open access, transparent peer-reviewed general medical journal. It is the flagship journal of the BMC series and publishes outstanding and influential research in various areas including clinical practice, translational medicine, medical and health advances, public health, global health, policy, and general topics of interest to the biomedical and sociomedical professional communities. In addition to research articles, the journal also publishes stimulating debates, reviews, unique forum articles, and concise tutorials. All articles published in BMC Medicine are included in various databases such as Biological Abstracts, BIOSIS, CAS, Citebase, Current contents, DOAJ, Embase, MEDLINE, PubMed, Science Citation Index Expanded, OAIster, SCImago, Scopus, SOCOLAR, and Zetoc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信